Biological E has place in India's COVID-19 vaccine market following Corbevax' approval

The Drugs Controller General of India (DCGI) recently approved Biological E’s Corbevax vaccine as the first heterogeneous COVID-19 booster vaccine in India for adults above 18 years who have received two shots of Covaxin or Covishield. Corbevax has the added advantage of scalability and thermostability, making it suitable for deployment in low-resource settings, says GlobalData.